Table 1.
Patient characteristics at initial diagnosis (n = 99).
| n (%) | |
|---|---|
| Age at diagnosis | |
| <12 months | 9 (9.1) |
| 12–18 months | 9 (9.1) |
| ≥18 months | 81 (81.8) |
| Gender | |
| Male | 59 (60.6) |
| Female | 40 (40.4) |
| Primary tumor site | |
| Adrenal | 82 (82.8) |
| Abdomen/pelvis | 13 (13.1) |
| Others | 4 (4.0) |
| Stage of disease at diagnosis | |
| Stage IIB | 2 (2.0) |
| Stage III | 8 (8.1) |
| Stage IV | 87 (87.9) |
| Stage IVS | 2 (2.0) |
| N-MYC Status (n = 86) | |
| Amplified | 34 (39.5) |
| Nonamplified | 52 (60.5) |
| Source of stem cells | |
| Peripheral blood stem cells | 57 (57.6) |
| Bone marrow | 42 (42.4) |
| Cytoreduction regimen used | |
| Carboplatin/etoposide/melphalan | 64 (64.6) |
| Carboplatin/etoposide/melphalan/TBI | 34 (34.3) |
| Carboplatin/wtoposide/cyclophosphamide | 1 (1.0) |
TBI: Total body irradiation.